Literature DB >> 7759610

Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis.

L Santambrogio1, G M Crisi, J Leu, G M Hochwald, T Ryan, G J Thorbecke.   

Abstract

Resistance to experimental allergic encephalomyelitis (EAE) induction by homogenized myelin (MSCH) in complete Freund's adjuvant (CFA) and pertussigen (P) in SJL mice was seen 1 week after intravenous injection of PLP 139-151 coupled to spleen cells (PLP-ECDI-SP). Although this resistance could be transferred by spleen cells enriched for CD8+ T cells and thus had a component of immunoregulatory T cells, it was primarily due to anergy, as it was reversible by four daily injections of interleukin (II)-2 starting 3 days after the PLP-ECDI-SP. Earlier treatment with IL-2 did not reverse the tolerance. In view of the known higher sensitivity to anergy induction of Th1 than of Th2 cells, a change in the cytokine balance in the response to MSCH+CFA after anergy induction might be responsible for the resistance to EAE induction. The effect of treatment with cytokines alone on induction of EAE was therefore also determined. Short-term (1-2 weeks) daily pretreatment with IL-2 (4000 U) or TGF-beta 2 (1 micrograms) somewhat decreased the susceptibility to subsequent EAE induction, but IL-4 (5 ng), IL-10 (5 micrograms) or IL-12 (50-200 ng) had no effect under those conditions, even if low doses of PLP were injected simultaneously. Daily injections of IL-4 over an 8-week period prior to immunization, however, significantly lowered the incidence of EAE. Simultaneous injections of IFN-gamma (2000 U/day) completely abolished this effect of IL-4. The effect of these cytokines administered immediately after the immunization with MSCH + CFA + P was also examined. As shown earlier, TGF-beta 2 (100-1000 ng/day) caused a marked protection when it was given intraperitoneally on days 5-9 after injection of MSCH + CFA. IL-4 (5 ng/day), in contrast, was very protective when administered on days 0-4 and less so when given on days 5-9 or even on days 0-12. IL-10 (1 microgram/day) was not protective under these conditions and IL-12 (50 ng/day) significantly increased the severity and mortality of EAE when given on days 0-4 after MSCH + CFA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759610     DOI: 10.1016/0165-5728(95)00022-t

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Intravenous tolerance effectively overcomes enhanced pro-inflammatory responses and experimental autoimmune encephalomyelitis severity in the absence of IL-12 receptor signaling.

Authors:  Denise C Fitzgerald; Guang-Xian Zhang; Shuo Yu; Melissa L Cullimore; Zhao Zhao; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2012-04-21       Impact factor: 3.478

Review 2.  Choosing drug therapy for multiple sclerosis. An update.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

3.  Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1.

Authors:  L Z Chen; G M Hochwald; C Huang; G Dakin; H Tao; C Cheng; W J Simmons; G Dranoff; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

4.  Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.

Authors:  Masha Fridkis-Hareli; Laura Santambrogio; Joel N H Stern; Lars Fugger; Celia Brosnan; Jack L Strominger
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

5.  Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis.

Authors:  L M Howard; A J Miga; C L Vanderlugt; M C Dal Canto; J D Laman; R J Noelle; S D Miller
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

6.  Induction and suppression of an autoimmune disease by oligomerized T cell epitopes: enhanced in vivo potency of encephalitogenic peptides.

Authors:  K Falk; O Rötzschke; L Santambrogio; M E Dorf; C Brosnan; J L Strominger
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

7.  Encephalitogenicity of murine, but not bovine, DM20 in SJL mice is due to a single amino acid difference in the immunodominant encephalitogenic epitope.

Authors:  J M Greer; C Klinguer; E Trifilieff; R A Sobel; M B Lees
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 4.414

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.